Handok, Actelion enter into licensing agreement

Handok Pharm and Actelion Pharmaceuticals Korea announced on October 7 that they have entered into a licensing agreement for Actelion’s clazosentan, an intravenous endothelin receptor antagonist.

Under the agreement, the two companies will jointly collaborate the pivotal phase III study of clazosentan (CONSCIOUS-2). The study will measure the clinical benefits of clazosentan through the prim...